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Could	university	patents	stand	in	the	way	of	universal
global	access	to	a	COVID-19	vaccine?
Would	it	be	right	for	publicly-funded	universities	to	profit	from	their	role	in	creating	a	COVID-19	vaccine?	Luke
McDonagh	(LSE)	looks	at	the	case	of	the	Oxford	University/AstraZeneca	collaboration,	noting	that	its	plans	to	offer
non-exclusive,	royalty-free	licences	only	apply	until	the	WHO	declares	the	pandemic	over.
If	we	want	to	ensure	universal	global	access	to	any	COVID-19	vaccine,	we	must	find	the	right	balance	between	the
important	work	being	done	by	publicly-funded	universities	and	private	enterprises	(such	as	pharmaceutical
companies),	as	well	as	the	role	for	state-granted	property	rights	for	newly	invented	medicines	(patents).
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The	brave	activists	who	led	the	campaign	for	affordable	HIV	medicines	in	South	Africa	in	the	late	1990s	highlighted
a	fact	that	at	the	time	was	largely	hidden	in	the	West:	maintaining	public	health	often	conflicts	with	the	interests	of
private,	patent-owning	companies.	As	drug	prices	have	risen	in	the	past	few	decades,	the	issue	of	access	to
medicines	has	belatedly	become	a	major	concern	in	the	UK	and	US.	In	2018	NHS	England	struggled	to	obtain	the
life-enhancing	cystic-fibrosis	drug	Orkambi	for	more	than	a	year,	with	Vertex	initially	rejecting	the	largest	offer	in
NHS	history	(£100m	per	annum)	until	a	deal	was	eventually	made	last	year.	The	Financial	Times	recently	reported
that	‘Big	Pharma’	views	the	crisis	as	a	‘shot	at	redemption’	and	‘investors	believe	the	crisis	will	ease	the	political
scrutiny’	that	has	hung	over	the	industry	in	the	wake	of	price	scandals	and	the	opioid	epidemic,	which	has	been
linked	to	the	OxyContin	patents	owned	by	the	Sackler	family	and	manufactured	by	Purdue.
COVID-19	has	made	concerns	over	access	to	medicines	truly	universal.	It	has	also	led	to	a	greater	focus	on	the
essential	role	of	universities	in	developing	vaccines	and	treatments.	It	is	important	to	consider	the	effect	of	UK
universities’	links	with	the	private	sector.	My	main	focus	is	the	relationship	between	Oxford	University	and
AstraZeneca	and	the	promising	COVID-19	vaccine	ChAdOx1	nCoV-19	developed	at	Oxford.	(At	the	time	of	writing
it	is	on	hold	after	one	of	the	participants	had	an	adverse	reaction.)
How	intellectual	property	apples	to	public	institutions	working	in	the
private	sphere
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The	public	role	that	universities	play	within	society	is	indisputable,	and	most	UK	universities	are	publicly-funded
institutions.	Yet	through	their	university	intellectual	property	(IP)	policies	and	technology	transfer	models,	they	are
also	actors	in	the	private	sphere.	Universities	commonly	apply	for	patents	on	their	research	outcomes	and	then
‘spin	out’	and	license	these	new	technologies	and	medicines.	The	overall	annual	total	for	UK	universities’	IP
revenues	amounts	to	more	than	£150	million.	Yet	success	has	been	uneven,	with	a	relatively	small	number	of	large
research-intensive	universities	achieving	lucrative	outcomes,	while	the	majority	of	institutions	focus	on	more	modest
efforts.	For	example,	the	figures	for	2017–18	show	a	wide	variance,	with	Oxford	University	(£53m)	by	far	the	most
successful,	followed	by	the	upper	tier	of	Queen’s	University	Belfast	(£22.1m),	University	College	London	(£14.7m),
University	of	Sheffield	(£12.7m),	and	the	University	of	Cambridge	(£8.1m),	and	several	other	high	profile	institutions
showing	revenues	towards	the	lower	end,	e.g.	Imperial	College	London	(£3.5m)	King’s	College	London	(£2.8m),
University	of	Edinburgh	(£2.39m),	Newcastle	University	(£1.76m),	City,	University	of	London	(£397,000).
When	public	universities	create	research	that	is	potentially	of	commercial	value,	tensions	between	public	goods	and
private	interests	inevitably	occur.	Yet	it	is	logical	that	innovative	research	on	COVID-19	should	benefit	the	public
first	and	foremost.	When	considering	how	best	this	can	be	achieved,	it	is	imperative	to	examine	the	appropriate	role
for	intellectual	property	(IP)	rights,	such	as	patents	(since	patenting	is	the	primary	method	of	protection	for	scientific
inventions).	How	can	we	ensure	that	university	research	benefits	the	public	(including	the	global	public)?	Can	the
exclusive	rights	and	licence	agreements	envisaged	by	the	patent	system	achieve	overall	public	welfare	goals,	or
are	they	ultimately	a	hindrance?
What	the	Oxford	University/AstraZeneca	agreement	says
A	potential	vaccine	(ChAdOx1	nCoV-19)	has	been	developed	at	the	UK’s	most	successful	IP	licensing	institution,
Oxford	University.	It	is	currently	undergoing	human	trials	in	Brazil.	Other	universities	may	also	end	up	owning
valuable	COVID-related	IP	in	the	form	of	patents,	design	rights	and	trade	secrets:	Imperial	College	London	is
working	on	a	potential	vaccine;	while	King’s	College	London	owns	an	innovative	prototype	ventilator,	OxVent,	which
recently	progressed	to	the	next	phase	of	safety	and	usability	testing.	But	Oxford’s	vaccine	currently	looks	the	most
promising,	and	as	such	the	issue	of	access	to	it	is	worth	exploring	in	detail.
The	University	of	Oxford	has	received	several	million	pounds	worth	of	UK	government	funding	for	the	development
of	this	vaccine	–	it	is	very	much	a	‘public-facing’	project	at	a	public	institution.	Yet,	after	apparently	initially
considering	a	completely	‘open’	licensing	approach,	Oxford	agreed	an	exclusive	partnership	with	the
pharmaceutical	giant	AstraZeneca	in	April	for	the	development	and	manufacturing	and	distribution	of	the	vaccine.
Partnering	with	an	experienced	manufacturer	and	distributor	of	medicines	makes	sense	given	the	need	to	produce
a	massive	amount	of	vaccine	quickly	and	at	scale.	Yet	there	are	concerns	at	how	this	deal	could	play	out.
The	Oxford-AstraZeneca	agreement	envisages	exclusive	rights	(via	patents	and	trade	secrets)	and	the	use	of	IP
licensing.	In	this	regard,	Oxford	University	Innovation	(OUI)	has	made	public	its	policy	for	third-party	access	to
university	IP	relevant	to	COVID-19.	It	has	five	aspects:
1.	OU	and	OUI	will	expedite	access	to	Oxford	IP	to	enable	global	deployment	at	scale	of	associated	products
and	services	to	address	the	COVID-19	pandemic
2.	The	default	approach	of	the	University	and	OUI	regarding	(1)	will	be	to	offer	non-exclusive,	royalty-free
licences	to	support	free	of	charge,	at-cost	or	cost	+	limited	margin	supply	as	appropriate,	and	only	for	the
duration	of	the	pandemic,	as	defined	by	the	WHO
3.	Licence	terms	for	supplying	downstream	(post-pandemic)	commercial	markets	will	be	the	subject	of	a
separate	agreement
4.	The	grant	to	a	Licensee	of	access	to	IP	under	(1)	does	not	guarantee	it	will	be	granted	downstream
commercial	rights
5.	Where	relevant	University	IP	is	licensed	to	support	commercial	sales	after	the	point	at	which	the	pandemic
is	declared	by	the	WHO	(or	other	appropriate	body)	to	be	over,	such	licences	will	carry	appropriate	financial
terms	to	allow	the	University	to	reinvest	proceeds	in	research	and	teaching.
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Thus	Oxford’s	default	approach	regarding	this	access	will	be	to	offer	non-exclusive,	royalty-free	licences	to	support
free-of-charge,	at-cost	or	cost	with	limited	margin	supply	as	appropriate.	This	sounds	reasonable	and	could,	in
theory,	help	ensure	global,	universal	access.	However,	there	is	a	caveat:	these	terms	will	only	apply	for	the	duration
of	the	pandemic,	and	OUI	expects	there	to	be	a	commercial	market	post-pandemic	that	would	allow	the	university
to	obtain	revenues.	The	definition	of	the	‘duration	of	the	pandemic’	will	be	crucial	–	what	happens	if	the	WHO
declares	the	global	pandemic	to	be	over,	but	localised	outbreaks	still	occur	in	developing	countries?
There	is	a	concern	that	in	a	desire	for	profit,	developing	countries	(and	their	populations)	could	be	priced	out	in	such
circumstances.	It	can	certainly	be	argued	that	it	is	immoral	that	one	of	the	world’s	wealthiest	public	institutions	is
seeking	to	make	a	financial	surplus	on	a	COVID-19	vaccine	developed	using	public	funds	(even	if	profits	are	only
achieved	after	the	pandemic	is	declared	over	by	the	WHO).
Oxford	University	Innovation’s	chief	operating	officer	Adam	Stoten	commented	in	April	that	he	did	not	envisage	any
problems	of	access:
“We	are	making	sure	we	have	good	alignment	with	UK	interests,	but	equitable	global	access	will	also	be
embedded	in	any	licence	we	grant…	The	negative	publicity	attached	to	asserting	your	IP	rights	would	be
very	large…	It	is	critical	for	companies	to	do	the	right	thing	and	be	seen	to	be	doing	the	right	thing.”
This	statement	indicates	that	Oxford	University	understands	that	global	access	must	be	the	priority.	But	the	proof
will	be	in	the	way	access	to	the	vaccine	actually	works	in	practice	over	the	coming	years.
Oxford	can	and	should	commit	to	open	licensing
Oxford	University	researchers	should	be	commended	for	their	innovative	vaccine	research,	which	may	yet	result	in
a	viable	vaccine.	OUI’s	statement	on	‘equitable	global	access’	shows	there	is	no	doubt	the	university	is	well	aware
of	its	responsibilities	towards	the	wider	world.	Nonetheless,	in	the	era	of	Black	Lives	Matter,	and	the	debate	over
reparations	from	those	institutions	that	benefited	from	funds	arising	from	slavery	and	colonialism,	Oxford	can	and
should	consider	doing	more.	The	university	should	commit	to	an	open	licensing	approach	for	all	developing	country
use	of	any	vaccine,	even	post-pandemic.	It	would	be	morally	perverse	if,	faced	with	a	truly	universal	disease,
publicly-funded	universities	develop	medicines	and	partner	with	private	companies	to	manufacture	at	scale,	only	to
end	up	ensuring	only	the	populations	in	rich	countries	actually	receive	access.
This	post	represents	the	views	of	the	author	and	not	those	of	the	COVID-19	blog,	nor	LSE.
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